Skip to main content

Table 1 Pathological and clinical data of the arrayed prostate cancers

From: High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer

  No. of patients (%)
Study cohort on TMAa Biochemical relapse among categories
Follow-up
 n 12,208 2759 (22.6%)
 Mean / median (month) 59 / 49
Age (y)
  ≤ 50 310 54 (17.4%)
 51–59 3278 656 (20.0%)
 60–69 7539 1693 (22.5%)
  ≥ 70 2251 501 (22.3%)
Pretreatment PSA (ng/ml)
  < 4 1659 242 (14.6%)
 4–10 7942 1355 (17.1%)
 10–20 2807 737 (26.3%)
  > 20 940 397 (42.2%)
pT stage (AJCC 2002)
 pT2 8646 1095 (12.7%)
 pT3a 2904 817 (28.1%)
 pT3b 1765 796 (45.1%)
 pT4 68 51 (75%)
Gleason grade
  ≤ 3 + 3 2638 264 (10.0%)
 3 + 4 7172 1436 (20.0%)
 3 + 4 Tert.5 645 165 (25.6%)
 4 + 3 1224 683 (55.8%)
 4 + 3 Tert.5 987 487 (49.3%)
  ≥ 4 + 4 756 531 (70.2%)
pN stage
 pN0 7899 1821 (23.1%)
 pN+ 855 546 (63.9%)
Surgical margin
 Negative 10,768 1833 (17.0%)
 Positive 2613 1059 (40.5%)
  1. Abbreviation: AJCC, American Joint Committee on Cancer
  2. a Numbers do not always add up to 13,660 in the different categories because of cases with missing data